- $155.48m
- $86.14m
- $41.02m
- 78
- 31
- 98
- 78
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 55.22 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -9.58% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.5 | ||
| Price to Tang. Book | 2.5 | ||
| Price to Free Cashflow | 23.89 | ||
| Price to Sales | 3.79 | ||
| EV to EBITDA | 27.88 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.76% | ||
| Return on Equity | 5.62% | ||
| Operating Margin | 3.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 22.06 | 29.66 | 27.18 | 31.79 | 41.02 | 49.82 | 58.94 | 12.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | -27.87 | +50 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Directors
- David Zacut CHM (67)
- Avner Hagai CCH (59)
- Christopher Von Jako PRE (51)
- R. Scott Areglado CFO
- Hadar Levy SVP
- Yiftach Roth CSO (49)
- Christopher Boyer VPR
- Ronen Segal VRD (43)
- Hila Rubinshtein MDR (34)
- Rami Itselev OTH (38)
- Amit Jino OTH (32)
- Daniel Azriel DRC (66)
- Yosef Ben Shalom DRC (65)
- Uri Elmaliach DRC (66)
- Avner Lushi DRC
- Gavriel Magen DRC (55)
- Karen Sarid DRC (67)
- Orly Uri DRC (60)
- Abraham Zangen DRC
- Ety Mitrany Rayten NED (46)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 7th, 2006
- Public Since
- December 24th, 2006
- No. of Employees
- 106
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 37,738,456
- Address
- 16 Hartum Street Rad Tower, JERUSALEM, 9777516
- Web
- https://www.brainsway.com/
- Phone
- +972 25813140
- Auditors
- Kost, Forer, Gabbay & Kasierer
Upcoming Events for BWAY
Similar to BWAY
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
As of Today at 19:41 UTC, shares in Brainsway are trading at $8.24. This share price information is delayed by 15 minutes.
Shares in Brainsway last closed at $8.24 and the price had moved by +63.17% over the past 365 days. In terms of relative price strength the Brainsway share price has outperformed the S&P500 Index by +53.42% over the past year.
The overall consensus recommendation for Brainsway is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBrainsway does not currently pay a dividend.
Brainsway does not currently pay a dividend.
Brainsway does not currently pay a dividend.
To buy shares in Brainsway you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $8.24, shares in Brainsway had a market capitalisation of $155.48m.
Here are the trading details for Brainsway:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BWAY
Based on an overall assessment of its quality, value and momentum Brainsway is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Brainsway is $14.51. That is 76.11% above the last closing price of $8.24.
Analysts covering Brainsway currently have a consensus Earnings Per Share (EPS) forecast of $0.13 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Brainsway. Over the past six months, its share price has underperformed the S&P500 Index by -9.23%.
As of the last closing price of $8.24, shares in Brainsway were trading -8.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Brainsway PE ratio based on its reported earnings over the past 12 months is 55.22. The shares last closed at $8.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Brainsway's management team is headed by:
- David Zacut - CHM
- Avner Hagai - CCH
- Christopher Von Jako - PRE
- R. Scott Areglado - CFO
- Hadar Levy - SVP
- Yiftach Roth - CSO
- Christopher Boyer - VPR
- Ronen Segal - VRD
- Hila Rubinshtein - MDR
- Rami Itselev - OTH
- Amit Jino - OTH
- Daniel Azriel - DRC
- Yosef Ben Shalom - DRC
- Uri Elmaliach - DRC
- Avner Lushi - DRC
- Gavriel Magen - DRC
- Karen Sarid - DRC
- Orly Uri - DRC
- Abraham Zangen - DRC
- Ety Mitrany Rayten - NED